Syngene International has concluded acquisition of multi-modal biologics manufacturing facility from Stelis Biopharma. The acquisition of the ‘Unit 3’ biologics manufacturing facility was concluded at a revised gross value of Rs 617 crore adjusted from the earlier gross value of Rs 702 crore. The reduction in gross value reflects the retention of certain equipment not currently installed in the facility by Stelis Biopharma.
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene. It also includes a commercial scale, high speed, fill-finish unit - an essential capability for drug product manufacturing.
The unit has been acquired effective December 01, 2023 on payment of Rs 395 crore. The balance, subject to final adjustments, will be paid in December 2023 on completion of certain post-closing actions by Stelis Biopharma.
Syngene International is India’s largest Contract Research Services Organization providing integrated discovery and development services for novel molecules across multiple platforms including small molecules, large molecules, Antibody-Drug Conjugates and Oligonucleotides.
Company Name | CMP |
---|---|
Syngene Internation. | 862.60 |
AGS Transact Tech | 96.36 |
Just Dial | 1141.00 |
Krystal Integrated | 716.70 |
Latent View Analytic | 461.70 |
View more.. |